Alpha Cognition initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Alpha Cognition (ACOG) with a Buy rating and $20 price target Alpha is an emerging specialty biopharmaceuticals company focused on commercializing a next-generation symptomatic therapy for mild-to-moderate Alzheimer’s disease, the analyst tells investors in a research note. The firm says benzgalantamine has been shown to eliminate sleep disturbances, while also carrying a very low rate of side effects. It expects the drug to retain all the efficacy of the native molecule while significantly improving the safety and tolerability profile. This should enable Alpha Cognition to generate $540M in peak annual sales, contends H.C. Wainwright.